We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
RNA category is based on mRNA expression levels in the analyzed samples (RNA assay description). The categories include: tissue/cell line enriched, group enriched, tissue/cell line enhanced, expressed in all, mixed and not detected. RNA category is calculated separately for The Cancer Genome Atlas (TCGA) data from cancer tissues and internally generated Human Protein Atlas (HPA) data from normal tissues and cell lines.
TCGA (cancer tissue):
Expressed in all
HPA (cell line):
Expressed in all
HPA (normal tissue):
Expressed in all
Protein evidencei
Protein evidence scores are generated from several independent sources and are classified as evidence at i) protein level, ii) transcript level, iii) no evidence, or iv) not available.
Evidence at protein level
Protein expression normal tissuei
A summary of the overall protein expression pattern across the analyzed normal tissues. The summary is based on knowledge-based annotation.
"Estimation of protein expression could not be performed. View primary data." is shown for genes analyzed with a knowledge-based approach where available RNA-seq and gene/protein characterization data has been evaluated as not sufficient in combination with immunohistochemistry data to yield a reliable estimation of the protein expression profile.
Cytoplasmic expression in several different tissue types.
IMMUNOHISTOCHEMISTRY DATA RELIABILITY
Data reliability descriptioni
Standardized explanatory sentences with additional information required for full understanding of the knowledge-based expression profile.
Antibody staining mainly not consistent with RNA expression data. Pending external verification.
Reliability score - normal tissuesi
Reliability score (score description), divided into Enhanced, Supported, Approved, or Uncertain, is evaluated in normal tissues and based on consistency between antibody staining pattern, available RNA-Seq and gene/protein characterization data, as well as similarity between independent antibodies targeting the same protein.
Kaplan-Meier plots for all cancers where high expression of this gene has significant (p<0.001) association with patient survival are shown in this summary. Whether the prognosis is favourable or unfavourable is indicated in brackets. Each Kaplan-Meier plot is clickable and redirects to a detailed page that includes individual expression and survival data for patients with the selected cancer.
Gene product is not prognostic.
Show all
RNA EXPRESSION OVERVIEWi
RNA expression overview shows RNA-seq data from The Cancer Genome Atlas (TCGA).
TCGA dataseti
RNA-seq data in 17 cancer types are reported as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA). RNA cancer tissue category is calculated based on mRNA expression levels across all 17 cancer tissues and include: cancer tissue enriched, cancer group enriched, cancer tissue enhanced, expressed in all, mixed and not detected. To access cancer specific RNA and prognostic data, click on the cancer name. The cancer types are color-coded according to which type of normal organ the cancer originates from.
Antibody staining in 20 different cancers is summarized by a selection of four standard cancer tissue samples representative of the overall staining pattern. From left: colorectal cancer, breast cancer, prostate cancer and lung cancer. An additional fifth image can be added as a complement. The assay and annotation is described here. Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.
For each cancer, color-coded bars indicate the percentage of patients (maximum 12 patients) with high and medium protein expression level. The cancer types are color-coded according to which type of normal organ the cancer originates from. Low or not detected protein expression results in a white bar. Mouse-over function shows details about expression level and normal tissue of origin. The images and annotations can be accessed by clicking on the cancer name or protein expression bar. If more than one antibody is analyzed, the tabs at the top of the staining summary section can be used to toggle between the different antibodies.
Most malignancies showed weak to moderate cytoplasmic positivity. Malignant gliomas, lymphomas and melanomas were negative.
GENE INFORMATIONi
Gene information from Ensembl and Entrez, as well as links to available gene identifiers are displayed here. Information was retrieved from Ensembl if not indicated otherwise.
Gene name
ZFP36L1 (HGNC Symbol)
Synonyms
Berg36, BRF1, cMG1, ERF1, RNF162B, TIS11B
Description
ZFP36 ring finger protein like 1 (HGNC Symbol)
Entrez gene summary
This gene is a member of the TIS11 family of early response genes, which are induced by various agonists such as the phorbol ester TPA and the polypeptide mitogen EGF. This gene is well conserved across species and has a promoter that contains motifs seen in other early-response genes. The encoded protein contains a distinguishing putative zinc finger domain with a repeating cys-his motif. This putative nuclear transcription factor most likely functions in regulating the response to growth factors. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2011]
The protein browser displays the antigen location on the target protein(s) and the features of the target protein. The tabs at the top of the protein view section can be used to switch between the different splice variants to which an antigen has been mapped.
At the top of the view, the position of the antigen (identified by the corresponding HPA identifier) is shown as a green bar. A yellow triangle on the bar indicates a <100% sequence identity to the protein target.
Under the antigens, the maximum percent sequence identity of the protein to all other proteins from other human genes is displayed, using a sliding window of 10 aa residues (HsID 10) or 50 aa residues (HsID 50). The region with the lowest possible identity is always selected for antigen design, with a maximum identity of 60% allowed for designing a single-target antigen (read more).
The curve in blue displays the predicted antigenicity i.e. the tendency for different regions of the protein to generate an immune response, with peak regions being predicted to be more antigenic.The curve shows average values based on a sliding window approach using an in-house propensity scale. (read more).
If a signal peptide is predicted by a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius (turquoise) and/or transmembrane regions (orange) are predicted by MDM, these are displayed.
Low complexity regions are shown in yellow and InterPro regions in green. Common (purple) and unique (grey) regions between different splice variants of the gene are also displayed (read more), and at the bottom of the protein view is the protein scale.
ZFP36L1-001
ZFP36L1-002
ZFP36L1-003
ZFP36L1-004
ZFP36L1-005
ZFP36L1-006
PROTEIN INFORMATIONi
The protein information section displays alternative protein-coding transcripts (splice variants) encoded by this gene according to the Ensembl database.
The ENSP identifier links to the Ensembl website protein summary, while the ENST identifier links to the Ensembl website transcript summary for the selected splice variant. The data in the UniProt column can be expanded to show links to all matching UniProt identifiers for this protein.
The protein classes assigned to this protein are shown if expanding the data in the protein class column. Parent protein classes are in bold font and subclasses are listed under the parent class.
The Gene Ontology terms assigned to this protein are listed if expanding the Gene ontology column. The length of the protein (amino acid residues according to Ensembl), molecular mass (kDalton), predicted signal peptide (according to a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius) and the number of predicted transmembrane region(s) (according to MDM) are also reported.
Predicted intracellular proteins Plasma proteins Cancer-related genes Mutational cancer driver genes Protein evidence (Kim et al 2014) Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000165 [MAPK cascade] GO:0000288 [nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay] GO:0000932 [P-body] GO:0001570 [vasculogenesis] GO:0003342 [proepicardium development] GO:0003677 [DNA binding] GO:0003700 [transcription factor activity, sequence-specific DNA binding] GO:0003723 [RNA binding] GO:0003729 [mRNA binding] GO:0005515 [protein binding] GO:0005634 [nucleus] GO:0005737 [cytoplasm] GO:0005829 [cytosol] GO:0006355 [regulation of transcription, DNA-templated] GO:0006397 [mRNA processing] GO:0006402 [mRNA catabolic process] GO:0006417 [regulation of translation] GO:0006810 [transport] GO:0006915 [apoptotic process] GO:0007275 [multicellular organism development] GO:0007507 [heart development] GO:0008283 [cell proliferation] GO:0009611 [response to wounding] GO:0010468 [regulation of gene expression] GO:0010837 [regulation of keratinocyte proliferation] GO:0014065 [phosphatidylinositol 3-kinase signaling] GO:0017091 [AU-rich element binding] GO:0021915 [neural tube development] GO:0030529 [intracellular ribonucleoprotein complex] GO:0031086 [nuclear-transcribed mRNA catabolic process, deadenylation-independent decay] GO:0031440 [regulation of mRNA 3'-end processing] GO:0032869 [cellular response to insulin stimulus] GO:0033077 [T cell differentiation in thymus] GO:0035264 [multicellular organism growth] GO:0035925 [mRNA 3'-UTR AU-rich region binding] GO:0038066 [p38MAPK cascade] GO:0043488 [regulation of mRNA stability] GO:0043491 [protein kinase B signaling] GO:0044344 [cellular response to fibroblast growth factor stimulus] GO:0045577 [regulation of B cell differentiation] GO:0045600 [positive regulation of fat cell differentiation] GO:0045616 [regulation of keratinocyte differentiation] GO:0045647 [negative regulation of erythrocyte differentiation] GO:0045657 [positive regulation of monocyte differentiation] GO:0045661 [regulation of myoblast differentiation] GO:0046872 [metal ion binding] GO:0048382 [mesendoderm development] GO:0048568 [embryonic organ development] GO:0051028 [mRNA transport] GO:0060710 [chorio-allantoic fusion] GO:0060712 [spongiotrophoblast layer development] GO:0061158 [3'-UTR-mediated mRNA destabilization] GO:0070371 [ERK1 and ERK2 cascade] GO:0071320 [cellular response to cAMP] GO:0071356 [cellular response to tumor necrosis factor] GO:0071364 [cellular response to epidermal growth factor stimulus] GO:0071375 [cellular response to peptide hormone stimulus] GO:0071385 [cellular response to glucocorticoid stimulus] GO:0071456 [cellular response to hypoxia] GO:0071472 [cellular response to salt stress] GO:0071560 [cellular response to transforming growth factor beta stimulus] GO:0071889 [14-3-3 protein binding] GO:0072091 [regulation of stem cell proliferation] GO:0097403 [cellular response to raffinose] GO:1900153 [positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay] GO:1901991 [negative regulation of mitotic cell cycle phase transition] GO:1902172 [regulation of keratinocyte apoptotic process] GO:1904582 [positive regulation of intracellular mRNA localization] GO:1904628 [cellular response to phorbol 13-acetate 12-myristate]
G3V382 [Direct mapping] mRNA decay activator protein ZFP36L1
Show all
SPOCTOPUS predicted secreted proteins Predicted intracellular proteins Cancer-related genes Mutational cancer driver genes Protein evidence (Ezkurdia et al 2014)
The Human Protein Atlas project is funded
MENU
